Glaucoma is a heterogeneous group of optic neuropathies that share characteristic pathognomonic changes to the optic disc and visual field. Glaucoma is a chronic neurodegenerative disease characterized by retinal ganglion cell loss. There are a number of risk factors associated with glaucoma, including age, ethnicity, and family history. The current standard of therapy for glaucoma involves lowering the intraocular pressure through medical, laser, and/or surgical therapy. Nevertheless, there are an increasing number of glaucoma patients that use alternative medicines to treat their glaucoma or supplement their traditional glaucoma management. Ginkgo biloba, Saffron, and medical marijuana are amongst the most commonly used medicinal plants by glaucoma patients. A neurodegenerative disease has a varied pathogenesis scenario, including elevated intraocular pressure, and hypoxic conditions in the retina. The current standard of care for treating glaucoma patients is therapeutic IOP lowering by topical ocular medicines, laser trabeculoplasty, and glaucoma filtration surgery. Several well-controlled clinical trials have demonstrated the importance of IOP-lowering therapy in all phases of the disease. This study explored emerging glaucoma pharmacotherapy approaches based on nanomedicines, such as liposomes, microsphere and nanoparticles. The goal of this article is to provide a thorough overview of the frontier developments, problems, and hotspots that have emerged in the field of nanomedicines, perhaps paving the way for future practical advancements.